I am a PhD pharmacologist by training who has focused the majority of my career in discovering a selective TAK1 inhibitor series. My pre-clinical work has provided significant insights into the signaling role of TAK1, in particular its correlation to TNF signaling. My lab has identified that TAK1 is an attractive target for many autoimmune diseases such as RA and systemic sclerosis. As a leader in this field, my primary goal is to advance the first TAK1 targeted inhibitors into the clinic. Since founding EydisBio, we have made great strides in identifying a selective chemical scaffold towards TAK1, optimizing our lead molecules and further understanding the competitive features of a TAK1 targeted therapies.